NasdaqGS - Delayed Quote • USD
AstraZeneca PLC (AZN)
At close: April 18 at 4:00 PM EDT
Pre-Market: 8:09 AM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 6 | 6 |
| Avg. Estimate | 1.21 | 1.32 | 4.56 | 5.13 |
| Low Estimate | 0.89 | 0.99 | 3.06 | 3.52 |
| High Estimate | 1.79 | 1.88 | 7.98 | 8.86 |
| Year Ago EPS | 0.96 | 1.08 | 3.63 | 4.56 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 8 | 8 |
| Avg. Estimate | 12.02B | 12.44B | 50.8B | 54.49B |
| Low Estimate | 11.78B | 12.36B | 49.85B | 52.45B |
| High Estimate | 12.44B | 12.55B | 51.43B | 55.65B |
| Year Ago Sales | 10.55B | 10.96B | 45.81B | 50.8B |
| Sales Growth (year/est) | 13.90% | 13.50% | 10.90% | 7.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 1.07 | 0.95 | 0.84 | 0.79 |
| EPS Actual | 0.96 | 1.08 | 0.87 | 0.72 |
| Difference | -0.11 | 0.13 | 0.03 | -0.07 |
| Surprise % | -10.30% | 13.70% | 3.60% | -8.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.21 | 1.32 | 4.56 | 5.13 |
| 7 Days Ago | 1.21 | 1.32 | 4.56 | 5.13 |
| 30 Days Ago | 1.25 | 1.35 | 4.56 | 5.14 |
| 60 Days Ago | 0.91 | 1.03 | 5.05 | 6.03 |
| 90 Days Ago | 1.01 | 1.24 | 4.3 | 5.11 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 2 | 2 |
| Up Last 30 Days | 1 | -- | 2 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 2 | -- | -- |
Growth Estimates
| CURRENCY IN USD | AZN | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 26.00% | -- | -- | 0.80% |
| Next Qtr. | 22.20% | -- | -- | 9.60% |
| Current Year | 25.60% | -- | -- | 4.50% |
| Next Year | 12.50% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 13.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | 16.82% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Upgrade | Deutsche Bank: Sell to Hold | 4/16/2024 |
| Maintains | BMO Capital: Outperform to Outperform | 2/12/2024 |
| Downgrade | Deutsche Bank: Buy to Hold | 2/8/2024 |
| Initiated | Morgan Stanley: Overweight | 1/23/2024 |
| Downgrade | Jefferies: Buy to Hold | 1/3/2024 |
| Upgrade | Jefferies: Hold to Buy | 9/25/2023 |
Related Tickers
NVS Novartis AG
92.57
-0.55%
GSK GSK plc
39.27
-0.83%
SNY Sanofi
45.39
-1.56%
MRK Merck & Co., Inc.
125.23
-0.11%
BMY Bristol-Myers Squibb Company
48.30
+0.96%
GILD Gilead Sciences, Inc.
66.16
-1.15%
AMGN Amgen Inc.
262.75
-0.50%
ABBV AbbVie Inc.
164.66
+0.25%
BIIB Biogen Inc.
190.52
-0.85%
LLY Eli Lilly and Company
745.95
-0.64%